(3R,5R)-7-[(1S,2S,6S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: (3R,5R)-7-[(1S,2S,6S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
• 化学式: C₂₃H₃₆O₇
• 分子量: 424.5
• InChiKey: TUZYXOIXSAXUGO-NZKZIZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• Process for the preparation of key intermediates for the synthesis of Statins
  申请人：F.I.S.- Fabbrica Italiana Sintetici S.p.A.

  公开号：EP2769979A1

  公开（公告）日：2014-08-27

  Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.

  本发明的对象是一种改进的工艺，用于合成他汀类药物的关键中间体的制备。
• [EN] CONVENIENT PROCESS FOR THE PREPARATION OF STATINS<br/>[FR] PROCÉDÉ PRATIQUE POUR LA PRÉPARATION DE STATINES
  申请人：ITALIANA SINT SPA

  公开号：WO2014128022A1

  公开（公告）日：2014-08-28

  Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.

  本发明的对象是一种改进的过程，用于制备合成他汀的关键中间体。
• Convenient Process for the Preparation of Statins
  申请人：F.IS.- FABBRICA ITALIANA SINTETICI S.P.A.

  公开号：US20150344439A1

  公开（公告）日：2015-12-03

  Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins.

  本发明的目的是提供一种改进的方法，用于合成他汀类药物的关键中间体的制备。
• CONVENIENT PROCESS FOR THE PREPARATION OF STATINS
  申请人：F.I.S.- Fabbrica Italiana Sintetici S.p.A.

  公开号：EP2867231B1

  公开（公告）日：2017-01-04
• Statins (HMG-COA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
  申请人：Mach Francois

  公开号：US20070003636A1

  公开（公告）日：2007-01-04

  The present invention relates to methods of causing MHC-class II or CD40 mediated immunomodulation, immunosuppression and anti-inflammatory action, in a subject suffering from or susceptible of suffering from a condition involving inappropriate immune response, which comprises administering to the subject at least one statin in an amount effective to modulate MHC class II or CD40 expression in the subject.